Studies investigating mepolizumab in allergic bronchopulmonary aspergillosis (ABPA) treatment in patients with cystic fibrosis (CF)

Author [ref.]Type of studyPatients nSex (M:F)Age (years)CF (yes/no)ABPA (yes/no)Reason for mepolizumab administrationObjectivesMepolizumab dosageTreatment durationFollow-upResultsBenefit (yes/no)
Zhang [39]Case series30:324–63Yes2 out of 3ABPA/ABPM with high AEC and systemic CSS dependenceEffect on: FEV1, total IgE, AEC, systemic CSS use, CF exacerbation rates100 mg every 28 days9–12 monthsNo↓ oral CSS use
= exacerbation rate
↓ total IgE
↓ AEC (2 out of 3)
↑ FEV1 (1 out of 3)
Boyle [40]Case report10:143YesYesCSS dependence
Side-effects with CSS, antifungal and omalizumab treatment
100 mg monthly20 monthsNoSystemic CSS stop
No ABPA exacerbations
= FEV1
= total IgE
Improved chest radiograph

M: male; F: female; ABPM: allergic bronchopulmonary mycosis; AEC: absolute eosinophil count; CSS: corticosteroids; FEV1: forced expiratory volume in 1 s.